BioPlus Acquisition Corp. Unit
BIOSU
BIOSU was delisted on the 6th of October, 2023.
0 hedge funds and large institutions have $0 invested in BioPlus Acquisition Corp. Unit in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $210K → $0 (-$210K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$209K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$542 |
BIOSU Hedge Fund Activity: Q4 2023 in Review
0 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Unit (BIOSU) for Q4 2023, worth a combined $0 — down 100% from $210K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIOSU and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Clear Street, exiting entirely with an estimated $209K sold.
- 0 institutional investors held BioPlus Acquisition Corp. Unit (BIOSU) as of Q4 2023, down from 2 in Q3 2023.
- Funds reported $0 of BioPlus Acquisition Corp. Unit stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new BioPlus Acquisition Corp. Unit positions in Q4 2023 and 2 closed out, a net change of -2 holders.
- The largest BioPlus Acquisition Corp. Unit seller in Q4 2023 was Clear Street, an estimated $209K sold.
Based on aggregated 13F filings for Q4 2023.